In conclusion, this study has given proof-of-principle demonstration that strategies leading to FGFR3 downregulation, which, to our knowledge, have not been attempted yet, could improve all skeletal features of ACH and related conditions and thus achieve superior outcomes than currently approved treatments. The gene discussed is FGFR3; the disease is achondroplasia.